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The recent years have witnessed an exponential increase in cancer research, leading to a considerable investment in the ﬁeld.
However, with few exceptions, this eﬀort has not yet translated into a better overall prognosis for patients with cancer, and the
search for new drug targets continues. After binding to the speciﬁc neurokinin-1 (NK-1) receptor, the peptide substance P (SP),
which is widely distributed in both the central and peripheral nervous systems, triggers a wide variety of functions. Antagonists
against the NK-1 receptor are safe clinical drugs that are known to have anti-inﬂammatory, analgesic, anxiolytic, antidepressant,
and antiemetic eﬀects. Recently, it has become apparent that SP can induce tumor cell proliferation, angiogenesis, and migration
via the NK-1 receptor, and that the SP/NK-1 receptor complex is an integral part of the microenvironment of inﬂammation and
cancer. Therefore, the use of NK-1 receptor antagonists as a novel and promising approach for treating patients with cancer is
currently under intense investigation. In this paper, we evaluate the recent scientiﬁc developments regarding this receptor system,
its role in the microenvironment of inﬂammation and cancer, and its potentials and pitfalls for the usage as part of modern
anticancer strategies.
1.Introduction
Cancer research in general has seen an endorsed and expo-
nential increase in the recent years and extensive ﬁnancial
venture and manpower have been invested in the ﬁeld.
Nonetheless, with the exception of very few specialized areas
suchas haematological cancersand perhapscertainskin can-
cers, this determination has not yet converted into a better
prospectforcancerpatients in general.Morganet al.recently
published an analysis on the contribution of chemotherapy
in adult malignancies with respect to 5-year survival [1]. In
this analysis, for 22 adult malignancies treated between 1990
and 2004, the overall contribution of curative and adjuvant
cytotoxic chemotherapy was estimated to be close to 2%.
Nevertheless,thereareseveralencouragingareasofinves-
tigation in cancer research. One ﬁeld of particular interest
is the identiﬁcation of the tumor microenvironment as an
essential part of tumor survival [2–4]. In better understand-
ing the biology of the tumors and the microenvironment in
which they ﬂourish, researchers hope to identify novel mo-
lecular targets for the therapeutical inhibition of tumor
growth. The neurokinin-1 (NK-1) receptor has recently been
discovered to play an integral role in the maintenance of
a favourable tumor microenvironment. Its pharmaceutical
blockage robustly inhibits tumor growth of various tumors,
making it an attractive anticancer target [5].
The NK-1 receptor is a tachykinin receptor. Three mam-
malian tachykinin receptors subtypes have been character-
ized, TACR1 (NK-1 receptor), TACR2, and TACR3,w h i c h
show preferential but not absolute selectivity for substance
P (SP), neurokinin A (NK-A), and neurokinin B (NK-B), re-
spectively [6, 7]. Tachykinin receptors are expressed by many2 The Scientiﬁc World Journal
diﬀerent cell types and respond to tachykinins in a cell
type-speciﬁc manner. The tachykinin receptors belong to the
G protein-coupled receptors (GPCRs). GPCRs comprise a
large family of membrane receptors involved in signal trans-
duction. These receptors are linked to a variety of physio-
l o g i c a la n db i o l o g i c a lp r o c e s s e ss u c ha sr e g u l a t i o no fn e u -
rotransmission, pain, inﬂammation, cell growth and diﬀer-
entiation, and oncogenesis, among others.
Tachykinins are signalling molecules that bind to speciﬁc
GPCRs on target cells. The NK-1 receptor is functionally
coupled with G protein, and by the usage of several tech-
niques including autoradiography, expression of mRNA en-
coding the NK-1 receptor protein, and immunocytochem-
istry, a widespread distribution of the NK-1 receptor has
been observed in both the mammalian central nervous sys-
t e ma sw e l la sp e r i p h e r a lt i s s u e s[ 8–12].
SP and the subsequent activation of the NK-1 receptor
lead to phosphoinositide hydrolysis [13], calcium mobiliza-
tion [14], and mitogen-activated protein kinase (MAPK)
activation [15, 16]. The activation of the NK-1 receptor was
foundtobeinvolvedinamyriadofprocessesrelatedtoonco-
genesis such as mitogenesis, angiogenesis, cell migration,
and metastasis. Therefore, SP and NK-1 receptor interaction
strongly inﬂuence the tumor microenvironment.
In this respect, it has been demonstrated that SP acts
through the NK-1 receptor as a mitogen in several human
cancer cell lines, including astrocytoma, melanoma, neurob-
lastoma,glioma,retinoblastomaaswellaspancreatic,larynx,
colon, and gastric carcinoma, leukemia, and breast cancer
[17–25].
Given the relevance of SP/NK-1 signaling in cancer,
substantial eﬀorts have been made to develop therapeutic
inhibitors of the NK-1 receptor [3, 5]. Importantly, NK-1 re-
ceptor antagonists are considered to have promising anti-
tumoral properties while having few side eﬀects. In this
paper,wereviewtherecentscientiﬁcdevelopmentsregarding
the NK-1 receptor and its biological inﬂuence in tumor
microenvironment and inﬂammation. The SP/NK-1 signal-
ing cascade has great potential for pharmaceutical tumor
targeting, and understanding of the role of NK-1 and its
ligand SP might help to design modern, speciﬁc anticancer
tumor strategies.
2. Interactionof SubstancePand the
TachykininReceptor
Human tachykinins are encoded by the TAC1, TAC3, and
TAC4 genes, which express SP, NK-A, and NK-B peptides
that interact with the tachykinin receptors NK-1, NK-2, and
NK-3, respectively [17]. Hemokinin-1 (HK-1) is the most
recent addition to the tachykinin family and demonstrates a
similar binding aﬃnity and preference for the NK-1 receptor
as others tachykinins. After binding to the NK-1 receptor, SP
regulatesavarietyofbiologicalfunctions[26–29].Ithasbeen
implicated in the regulation of the cardiovascular system,
in the dilatation of the arterial vascular system, in neuronal
survival and degeneration, in the regulation of respiratory
mechanisms, in sensory perception, in movement control,
Figure 1: Immunohistochemical staining of the NK-1 receptor in a
primary invasive malignant melanoma. A high expression of NK-1
receptor (arrow) was observed in the cytoplasm of the tumor cells.
Cell nuclei were counterstained with hematoxylin (x 40).
in gastric motility, in salivation, in micturition [30–32], in
pain, and in depression [33–35]. The neuropeptide SP has
also been implicated the process of wound healing where it
facilitates neurogenic inﬂammation [36, 37].
Both SP and the NK-1 receptor are overexpressed in sev-
eral cancers including breast, ovarian, prostate, pancreas,
leukemia, and thyroid cancer as well as glioblastoma, among
others[5,17,18].Inbreastcancer,theinvolvementofSPand
its receptor has been widely described for the acquisition of
oncogenic properties and in the formation of bone marrow
metastasis[38–41].ActivationofNK-1receptorbySPresults
in the activation of PI3K, the NF-kB pathway, and (MAPKs).
It has also been observed that SP can induce signal transduc-
tion through the NK-1 receptor by transactivating additional
receptors. These receptors include receptors with tyrosine
kinase activity, such as, for example, receptors belonging to
the ErbB family, including EGFR and Her2. This eﬀect was
described in several cell types [42–44]. Furthermore, SP has
been implicated in angiogenesis by inducing the formation
of capillary-like structures from endothelial cells placed on a
Matrigelmatrix[45]. Activation of NK-1 receptors by SP can
directlystimulatetheprocessofneovascularization,probably
through the induction of endothelial cell proliferation. SP-
enhanced angiogenesis most likely results from a direct
action on microvascular NK-1 receptors [46].
In general, overexpression of immunoreactive NK-1 re-
ceptors is clearly conﬁned to the plasma membrane of tumor
cells although immunoreactivity at times shows a diﬀuse
cytoplasmicstaining[25].Inthisregard,NK-1receptorvisu-
alization with immunohistochemical methods has facilitated
the identiﬁcation of tumors with a suﬃcient degree of recep-
tor overexpression for diagnostic or therapeutic intervention
using NK-1 receptor antagonists [47]( Figure 1).
Previous reports have shown that diﬀerent isoforms of
t h eN K - 1r e c e p t o rc a nb ef o u n di nb o t hh u m a n[ 48–51]a n d
rat tissues [51, 52], the isoform sizes of the latter ranging
from 46kDa to 54kDa. For instance, in human lymphocytes,
a glycosylated NK-1 receptor of 58kDa is found [49], where-
as this form and another two forms of 38kDa and 33kDa
are also present in IM9 lymphoblasts [50, 51]. In the last few
years, in several human tumor cell lines, the presence of four
more abundant isoforms (75, 54–58, 46, and 33–38kDa)The Scientiﬁc World Journal 3
of the NK-1 receptor has been described. Thus, in neu-
roblastoma SKN-BE(2), a major 54kDa band is observed,
whereas in the glioma GAMG cell line, an additional band of
33–38kDa is seen [20]. In IMR-32 neuroblastoma cell lines,
KELLY neuroblastoma cells, and T-ALL BE-13 cells, a band
of 33kDa and a major 54–58kDa band are observed, and in
IMR-32 neuroblastoma cells and B-ALL SD-1 cells, an addi-
tional isoform of about 75kDa has been detected [18, 53].
In the pancreatic carcinoma CAPAN-1 and PA-TU 8902 cell
lines, bands of 75, 58, 46, and 34kDa have been described
[54, 55]. The presence of 75, 58, and 33kDa isoforms of the
NK-1receptorinthehumanretinoblastomaWERI-Rb-1and
Y-79 cell lines has been reported [53]. Moreover, isoforms of
75, 58, 46, and 34kDa were observed in the human larynx
carcinoma HEp-2 cell line and the gastric adenocarcinoma
23132/87 cell line, whereas the colon adenocarcinoma SW-
403 cell line expressed isoforms of 75, 58, and 34kDa [23,
25]. It should be noted that tumor cell lines as diﬀerent
as human retinoblastoma, neuroblastoma, glioma, larynx
carcinoma, gastric and colon adenocarcinoma, and pancreas
carcinomaexpressedthesameisoformsoftheNK-1receptor.
In the future, the functional roles of the diﬀerent isoforms
of the NK-1 receptor observed in human cancer cells must
be investigated, since their functional roles are currently
unknown.
It is important to consider not only the qualitative but
also the quantitative expression of NK-1 receptors by tumor
cells, since it has been demonstrated that NK-1 receptor ex-
pression is increased 25–36-fold in human pancreatic cancer
cell lines in comparison with normal controls, and that
tumor samples from patients with advanced tumor stages
exhibit signiﬁcantly higher NK-1 receptor levels [55]. Thus,
the number of NK-1 receptors expressed in normal human
cells is lower (e.g., human blood T-lymphocytes express
7,000–10,000 NK-1 receptors/cell) [56] than that expressed
in human tumor cells (e.g., astrocytoma cells express 40,000
NK-1 receptors/cell) [57]. An increased percentage of NK-
1 receptor expression has also been reported in astrocytoma
and glioblastoma tumors possessing the most malignant
phenotypes, and the expression of NK-1 receptors is believed
to correlate with the degree of malignancy. For example,
glioblastomas express more NK-1 receptors than astrocy-
tomas [58]. Moreover, it has been described that primary
astrocytoma/glioma tumors express more NK-1 receptors
than do established astrocytoma/glioma cell lines in culture
[15]. Finally, the expression of mRNA coding the NK-1
receptor is increased in malignant tissues but not in benign
tissues (e.g., breast biopsies) [41].
2.1. NK-1 Receptor Activation and Signalling. SP preferen-
tially binds to the G protein-coupled NK-1 receptor [59].
The coupling of GPCRs, also called serpentine receptors,
to diﬀerent G proteins is dictated by the receptor’s amino
acid sequence, particularly in the cytoplasmic loops and the
carboxy-terminal tail of the receptor. This G complex con-
sists of three diﬀerent subunits: Gα subunit that binds
GDP/GTP, and Gβ and Gγ subunits that form the complex
Gβγ. The activation of the receptor by an agonist induces
the Gα subunit to change GDP by GTP and its dissociation
from the Gβγ dimer, which has strong unions among its
subunits Gβ and Gγ. The subunits Gα and Gβγ (the kinase
Src) then dissociate from the receptor and induce their own
signalling cascade. G protein Gβγ subunits recruit com-
ponents of the ras-dependent cascade, such as shc, grb2,
and src, leading to the activation of raf-1 and MAP kinase
1, a speciﬁc activator of ERK1y2 [60]. Once activated by its
ligand SP, the NK1 receptor activates members of the MAPK
cascade, including extracellular signal-regulated kinases 1
and 2 (ERK1/2) and p38MAPK. There are at least three
diﬀerent MAPKs: the extracellular signal-regulated kinase
(ERKs), c-Jun NH2 terminal kinase (JNKs), and p38 MAPK.
All have in common that they ultimately phosphorylate pro-
teins related to the regulation of gene expression. In their
activated state, the described pathways can lead to both
growth and induction of apoptosis [61, 62]. The mecha-
nisms by which these seemingly contradictory signals are
conveyedispoorlyunderstoodalthoughanemergingrolefor
scaﬀolding protein complexes that determine the subcellular
localization and consequent speciﬁcity of signaling proteins
may provide an explanation [16, 63, 64]. The most com-
monly studied mechanism by which GPCRs activate MAPK
is the release of G protein βγ subunits [63]. On the other
hand, tyrosine kinase receptors (TKRs) comprise a family
of cell surface proteins including most of the receptors for
growth factors such as the ErbB family. Many TKRs share
signalling pathways, and the biological responses speciﬁc to
each receptor seem to depend more on the cell context
than on any other factor. The ErbB family of receptors is
composed of four members: EGFR (Her1), Her2, Her3, and
Her4. The activation of an ErbB receptor by its ligands (with
the exception of Her2, which lacks a ligand-binding domain)
induces receptor dimerization, the activation of its intrinsic
tyrosine kinase activity, and the transphosphorylation of the
tyrosine residues present in its C-terminal domain of EGFR
can be then recognized by various eﬀector molecules that
are responsible for spreading the signal as PLCγ and c-
Src. The phosphorylation of these receptors, such as EGFR,
also induces the tyrosine phosphorylation of the adapter
protein SHC and the association of SHC with Grb2. Grb2
is constitutively associated with Sos1, a molecule responsible
for catalyzing the exchange of GDP for GTP in Ras. Ras
is a GTP-binding protein, which is anchored in the cell
membrane and that once activated stimulates the above-
mentioned MAPKs. These include MAPKKK, also known as
Raf, which phosphorylates MAPKK, also known as MEK,
which in turn is a component of the MAPK signaling
pathway (Figure 2). Regarding Her2, the formation of a Src-
Her2 heterocomplex has been described in breast cancer
cell lines and in human tumors although the exact residue
phosphorylated in Her2 remains unknown [65].
2.2. The SP/NK-1 Receptor Complex. It has been reported
that upon exposure to the agonist SP, this peptide and
its receptor are internalized into early endosomes within
minutes of binding [67–70], that the loss of NK-1 receptors
from the cell membrane is blocked by the inhibition of4 The Scientiﬁc World Journal
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Figure 2: The downstream signaling pathways of the NK-1 receptor are shown. Activation of this receptor by SP leads to cell proliferation,
antiapoptotic eﬀect, and cell migration (see detailed description in text. Ampliﬁed from Mu˜ noz et al. [66]).
clathrin-mediated endocytosis, and that the recovery of NK-
1 receptor expression at membrane level requires endosomal
acidiﬁcation but not novel protein synthesis. Internalized
SP is intact in early endosomes but is slowly degraded in
perinuclear vesicles [69]. Thus, SP induces a clathrin-de-
pendent internalization of the NK-1 receptor; the SP/NK-1
receptor complex dissociates in acidiﬁed endosomes, and SP
is then degraded, whereas the NK-1 receptor recycles to the
cell surface [69]. β-arrestin, originally thought only to medi-
ate receptor uncoupling and internalization, is required for
activation of ERK1/2 by a number of GPCRs [16, 64, 71, 72].
As described above, the involved MAPKs phosphorylate pro-
teins that then alter gene expression [73]( Figure 2). β-
arrestin forms a complex with the internalized receptor,
raf-1, and ERK1/2, retaining the activated kinases in the
cytosol [16]. Thus, scaﬀolding complexes can determine the
subcellular location and speciﬁcity of ERK1/2 and thereby
govern the mitogenic potential of a given signal. A diﬀerent
β-arrestin complex, containing the β2-adrenergic receptor
(β2-AR) and the tyrosine kinase src, also leads to ERK1/2
activation [64], but this signalling pathway mediates a
distinct set of cellular responses, possibly because of diﬀerent
subcellular localization of the activated kinases. SP induces
the formation of a multiprotein complex containing NK-1
receptor, β-arrestin, src, and ERK1/2, which forms close to
the plasma membrane. Once activated, ERK1/2 translocates
to the nucleus to induce proliferation and to protect from
apoptosis [16] (see Figure 2).
Some studies have indicated that the stimulation of the
NK-1 receptor located in human glioblastoma cells by SP
increases the phosphorylation and the activity of Akt or the
protein kinase B (EC 2.7.11.1), a serine-threonine protein
kinase that becomes activated via phosphatidyl-3-kinase
(PI3K). The activation of Akt suppresses apoptosis [74, 75]
(Figure 2). This is an important ﬁnding, because in glioblas-
toma, the basal activity of Akt is linked to a poor prognosis
[76].
Interestingly, it also has been observed that NK-1 expres-
sion was related to the tumor cell subtype, being higher in
the luminal cell lines expressing Her2 (SKBR3, BT474, and
MDA-MD-453) than in the basal-like cell lines (MDA-MB-
468, MDA-MB-231, MCF10A, and MCF12A). Moreover, the
proapoptotic eﬀectof NK-1 inhibition (as judged by annexin
V positivity) was greater in cells with higher levels of NK-1
expression, suggesting “oncogenic addiction” of these cells to
NK-1 signaling [42].
3. Tumor Microenvironment and
theNK-1 Receptor
Traditionally, in cancer research, scientists have focused on
the cancer cell itself. Only recently the microenvironmentThe Scientiﬁc World Journal 5
of tumors has been identiﬁed as an integral part of tumor
growth and survival. The microenvironment of tumors
includes any given interaction of the tumor cell with its
surroundings, whether these are molecular or cellular struc-
tures. Integral components of the microenvironment of tu-
mors include but are by no means limited to epithelial
cells, ﬁbroblasts and other stromal cells, extracellular matrix,
autocrine and paracrine cytokines and their receptors, cell-
to-cell contact among tumor cells and/or immune cells,
angiogenesis, residence of cancer stem cells (CSCs), and
many others. The tumor microenvironment has been shown
to restrict the eﬀectiveness of the antitumor immune re-
sponse by displaying a variety of immunosuppressive strate-
gies, making many eﬀective anticancer treatment strategies
used to date futile.
3.1.Angiogenesis. Neovascularizationorneoangiogenesisisa
sequential process. Early endothelial proliferation is followed
by new vessel formation and increased blood ﬂow accompa-
nied by maturation of endogenous neurovascular regulatory
systems [77]. Importantly, neoangiogenesis, which is consid-
ered a hallmark of tumor development, has been associated
with increased tissue innervation and expression of NK-1
receptors. It is also known that in a large majority of tumors,
SP and NK-1 receptors are found in the intra- and peritu-
moral blood vessels [58], and that SP, a main mediator of
neurogenic inﬂammation through the release of the peptide
from peripheral nerve terminals, is involved in the growth of
capillary vessels in vivo and in the proliferation of cultured
endothelial cells in vitro. Moreover, it is known that the
proliferation of endothelial cells by NK-1 receptor agonists
increases in a concentration-dependent manner whereas the
action of selective NK-2 and NK-3 receptor agonists has no
signiﬁcant eﬀects on the proliferation of endothelial cells.
These ﬁndings indicate that NK-1 receptor agonists (e.g.,
SP) can directly stimulate the process of neovascularization,
probably through the induction of endothelial cell prolifera-
tion, and thatSP-enhanced angiogenesis results froma direct
action on microvascular NK-1 receptors [46]. Thus, through
such receptors found at high density in blood vessels, SP
maystronglyinﬂuencevascularstructureandfunctioninside
and around tumors by increasing tumoral blood ﬂow and by
fosteringstromaldevelopment,consequentlyinﬂuencingcell
proliferation, survival, and migration [58].
3.2. Metastasis. One model for the development of metasta-
sis is based on the ﬁnding that GPCRs regulate the migratory
activity of tumor cells in a similar way as the recruit-
ment and homing of leucocytes. Furthermore, ligands (e.g.,
neurotransmitters) to these receptors can induce directed
chemotactic migration [78].
Migration is a prerequisite for invasion and metastasis
and is dependent on signaling substances of the immune and
neuroendocrine systems. The NK-1 receptor is an important
regulator of motility in a variety of cells [79–83]. A recent
study demonstrated that activation of the NK-1 receptor
triggers complex and rapid cellular shape changes, including
blebbing, in HEK293 cells. The cellular shape changes can
be quantiﬁed using a cellular assay based on electrical
impedance measurements in cellular monolayers. The NK-
1receptor-induced blebbingisnotassociatedwithapoptosis,
andthemainintracellularsignalingmechanismsactivatedby
the NK-1 receptor that are responsible for SP-induced cellu-
larshapechangeshavebeenidentiﬁed.Cellshapechangesare
dependent on Rho/Rock activation and are independent of
phospholipase C activation, cytosolic calcium increase, and
PKC activation [84] (see Figure 2).
The NK-1 receptor also plays an important role in breast
cancer cell growth and in the integration of these cells into
the bone marrow [41]. The NK-1 receptor is located on lipid
rafts and caveolas, with its activity totally dependent on the
microarchitecture of the cell membrane, as observed when
cells are depleted of cholesterol. When the NK-1 receptor
is activated by SP, the protein PKC is relocated on lipid
rafts [85]. It appears that the NK-1 receptor can transac-
tivate EGFR in glioblastoma cells, a process that probably
depends on the colocation of both receptors in membrane
microdomains [43]. In fact,it has been observed via confocal
microscopy that EGFR colocalizes with lipid rafts and that
the integrity of these lipid rafts is necessary for induction of
chemotaxis by EGF [86].
3.3. Haematopoiesis and Cancer Stem Cells. Understanding
the earliest development in cancer formation and progres-
sionisessentialforintroducingnewanticancertargets.There
are currently two hypotheses discussed that describe the
natural progression of tumor cells. On the one hand, it is
believedthatanycellwithinacanceroustumorhastheability
to form and maintain the tumor mass. This is called the
stochastic hypothesis [87]. The second, the so-called hierar-
chical hypothesis, suggests the existence of specialized CSCs
[87–90].CSCsareararepopulationofcancercellsexhibiting
stem cell properties, such as self-renewal, diﬀerentiation,
and tissue restoration. These stem cells are in a particular
niche,haveadeﬁnedprogenitorphenotype,higherresistance
to chemotherapy and radiotherapy, and are also capable
of invading and migrating to other tissues [87]. Therefore,
beside the initiation of the primary tumor, CSCs have been
associatedwithmetastasisformationandcancerrelapse[90].
Given the fact that the concept of CSCs has evolved
very recently, it is not surprising that there exists to date so
scarce literature regarding the expression and function of the
SP/NK-1 receptor system in CSCs. Nevertheless, the crucial
role of the SP/NK-1 receptor system in the development,
maintenance, and spread of cancer mandates intense study
of this receptor system in CSCs and related cells, such as
metastatic CSCs (mCSCs). mCSCs are believed to be a spe-
cialized population within CSCs and have been proposed to
be the essential seeds that initiate tumor metastasis [91]. Few
data regarding this highly interesting scientiﬁc area do exist.
For example, Li et al. studied the expression of SP and the
NK-1 receptor in the established human stem cell line TF-
1 and in primary stem cells derived from human placental
cord blood (HPCB) and demonstrated that both SP and NK-
1 are expressed in these cells [92]. We did not ﬁnd literature6 The Scientiﬁc World Journal
analysing the SP/NK-1 receptor system in specialized CSCs.
In recent reviews regarding CSCs, no mention of NK-1 or SP
is made, supporting the need for further investigation in this
matter [87–90].
In comparison, the role of SP and other tachykinins in
physiological haematopoiesis is well established [93–95].
Additionally, tachykinins and their interaction with their
receptors seem to be important in the neoplastic transfor-
mation of bone marrow, leading to the development of acute
leukaemia and other haematological cancers [93, 96, 97].
HK-1 is known to have a crucial role in the regulation of
bone marrow microenvironment, both physiologic and to-
wards malignant transformation [98]. For example, in a ta-
chykinin 4 gene knockout mouse (TAC4−/−), the early
stages of B lymphocyte development are altered, leading to
an increase of CD19(+)CD117(+)HSA(+)BP.1(−)“ f r a c t i o n
B”pro-Bcellsinthebonemarrow,whereaspre-B,immature,
and mature B cells are unaﬀected. TAC4 encodes for the
HK-1 receptor. These ﬁndings suggest an inhibitory role
for HK-1 on developing B cells, and that it is part of the
bone marrow microenvironment that supports and regulates
the proliferation and diﬀerentiation of hematopoietic cells
[96]. In another study, the presence of SP in B lymphocytes
of hypoplastic bone marrow predicted neoplastic transfor-
mation [97]. Also, HK-1 enhances B-cell proliferation and
antibody production [99], promotes survival of dendritic
cells [100], enhances the proliferation of T-cell precursors,
and increases the number of thymocytes [101]a sw e l la s
decreases blood pressure [102].
Taken together, the described ﬁndings strongly suggest
that SP and its interaction with the NK-1 receptor have a
critical role in the tumor microenvironment. The SP/NK-1
receptor complex should be considered as a universal mito-
gen in NK-1 receptor-expressing tumor cell types, as it gov-
erns not only the neoangiogenesis andgrowth of the tumoral
mass, but also the peritumoral inﬁltration and metastasis.
Obviously, this is especially relevant in those tumor cells
and tumoral and peritumoral tissues in which the SP/NK-1
receptor system is highly overexpressed, the later of which
can include inﬂammatory cells, ﬁbroblasts, blood vessels,
nerves, and ganglia, as described above. SP stimulates mito-
genesis and exerts an antiapoptotic eﬀect by activating NK-1
receptors in tumor cells mainly via four mechanisms: (1)
through an autocrine mechanism, by which SP is secreted
from primary tumors, (2) through a paracrine mechanism,
by which SP is released from tumor cells acting on endothe-
lial cells and on other surrounding cells in the tumor
microenvironment, (3) through means of the peripheral
nervous system, since SP is released from peripheral nerve
terminals, and possibly, (4) through an endocrine mecha-
nism, related to emotional behaviour, by which SP reaches
the peripheral tumors through the blood stream [66].
4. SubstanceP andthe NK-1 Receptor in
Inﬂammation and Cancer
Several levels of evidence indicate that SP plays a role in
regulating neurogenic inﬂammation and immune responses
in both peripheral tissues and in the central nervous system,
as well as in pain [59, 70]. It is known that SP is a potent
vasodilator in several peripheral tissues, that terminal nerve
endings containing SP are located close to blood vessels,
that the release of SP in peripheral tissues reproduces many
of the physiological changes seen in acute inﬂammation,
for example, plasma extravasation, and that a dramatic
upregulation in the expression of the NK-1 receptor occurs
during painful chronic conditions [103–108].
The SP/NK-1 receptor system can modulate the immune
function from sensory nerves via neurogenic inﬂammation.
Moreover, it is known that activation of the SP/NK-1 recep-
tor system produces alterations in the humoral [107]a n d
cellular, normal [108, 109], and tumoral immune response
[20–25, 53]. Also, it has been reported that tachykinins are
capable of modifying the response of a variety of inﬂamma-
tory cells, including mast cells, granulocytes, lymphocytes,
monocytes, and macrophages, and that oedema formation is
inducedbylowerconcentrationsofSPandisblockedbyNK-
1r ec e pt o ra n t a g o n i s t s[77].Finally,SPregulation of immune
cell function could originate not only from neuronal sources
such as sensory nerves and neurogenic inﬂammation, but
also from nonneuronal elements, such as eosinophils and
macrophages, in which the expression of both SP and the
NK-1 receptor is upregulated during inﬂammation [110,
111].
In addition, an increase in the levels of SP has been
described during intestinal inﬂammation, and a signiﬁcant
correlation between the degree of inﬂammation and the
clinical status of the disease has been implied [112, 113].
These observations indicate that local release of SP (e.g., in
lymph nodes) might be a factor contributing to the immune
disorder underlying chronic inﬂammatory bowel disease,
since the presence of speciﬁc SP receptors on human periph-
eral blood T lymphocytes has been demonstrated [114]. SP
does not act solely as neurotransmitter but can also function
as a proinﬂammatory cytokine participating in acute inﬂam-
mation and activating proteins involved in cell proliferation.
Interestingly, there is data to support a pathognomonic
connection between inﬂammation and cancer with regards
to the SP/NK-1 receptor complex. One of the theories that
explains how an inﬂammatory process could induce or pro-
mote cell transformation suggests that a cancer is generated
by a “wound that does not heal” [115, 116], or in other
words, that cancer could be originated from a tissue that
has suﬀered an improper repair after an injury. The mech-
anism of tissue repair seems also to be mediated by TKRs
transactivation and, in some cases, the activation of these
receptors is essential for proper tissue repair. Therefore, an
erroneous or prolonged repair process would create a source
of continuous stimulation of diﬀerent receptors that eventu-
ally could induce cellular transformation [42].
Chronic inﬂammation is well documented to correlate
with an increased risk of developing cancer [117], since
inﬂammation increases both mitogenesis and mutagenesis
[118]. It is also known that a dividing cell has a greater
risk of mutation than a quiescent cell [119]. Cell division
allows adducts to convert to mutations. The time interval
for DNA repair during cell division is short, and endogenousThe Scientiﬁc World Journal 7
or exogenous damage is therefore generally increased if cells
are proliferating. Moreover, it is well established that cancer
arises in chronically inﬂamed tissue, and this is particularly
notableinthegastrointestinaltract[120].Inﬂammationmay
become chronic either because an inﬂammatory stimulus
persists or because of dysregulation in the control mecha-
nisms that normally turn the process oﬀ.I th a sb e e nr e -
ported that many of the cells, cytokines, and additional proc-
esses such as leukocyte migration, dilatation of the local
vasculature, and angiogenesis involved in inﬂammation are
found in a variety of tumors.
Chronic inﬂammation caused by intestinal ﬂora leading
to inﬂammatory bowel disease such as ulcerative colitis and
Crohn’sdiseaseisclearlylinkedtoahigherincidenceofcolon
cancer. Moreover, elevated levels of SP and upregulated NK-
1 receptor expression have been reported in the rectum and
colon of patients with inﬂammatory bowel disease [121].
A very important study regarding the correlation of inﬂam-
mation and cancer with regards to the NK-1 receptor was
recently published by Gillespie et al. [122]. In this study,
archival formalin-ﬁxed paraﬃn-embedded colonic tissue
from patients with ulcerative colitis who developed carci-
noma or high-grade dysplasia was examined for changes in
expression of the NK-1 receptor. They found the levels of
the NK-1 receptor to be increased by 40% in high-grade
dysplasia and 80% in carcinoma compared with quiescent
colitis, therefore concluding a functional role for the NK-
1 receptor in malignant transformation in colitis-associated
cancer.
Analogously, dietary intake of proinﬂammatory carcino-
gens has been associated with prostate cancer. Chronic
inﬂammation resulting from esophageal reﬂux gives rise
to gastroesophageal reﬂux disease (GERD) and Barrett’s
esophagus, which is proven to be linked to a higher incidence
of cancer. Chronic Helicobacter pylori infection produces
chronic inﬂammation and is a documented potential risk
factor for stomach cancer [123]. It is also known that the
risk of pancreatic cancer is signiﬁcantly elevated in subjects
with chronic pancreatitis and appears to be independent
of sex, country, or type of pancreatitis [124]. Likewise, the
upregulation of mRNA expression coding for the NK-1
receptor has been reported in chronic pancreatitis, with a
strong relationship to the pain syndrome in these patients
[125]. It is important to note again in this context that in
the vast majority of tumors, investigated NK-1 receptors
were found in intratumoral and peritumoral blood vessels
[58], and that NK-1 receptors are highly expressed in blood
vessels not only within the tumor mass but also in the
p e r i t u m o r a lt i s s u e[ 55]. All these observations suggest that
chronic inﬂammation could enhance cancer through the
SP/NK-1 receptor system, which is upregulated in the proc-
ess of chronic inﬂammation. In this regard, it has been
demonstrated that SP stimulates mitogenesis [18–21, 23–
25, 53, 126, 127], and that NK-1 receptor expression is
increased in cancer cell lines in comparison with normal
controls [55]. In addition, the growth of the tumor mass,
peritumor inﬁltration, and metastasis could be regulated by
the SP/NK-1 receptor system overexpressed in tumor cells
and in tumor and peritumor tissues [55].
Nevertheless, despite the overwhelming evidence stated
between chronic inﬂammation and the formation of cancer,
recent evidence also suggests that the speciﬁc activation of
the immune system and thereby creation of an immune
response might actually be highly beneﬁcial in the treatment
of cancer [128, 129]. In this promising concept called im-
munostimulation, regulatory dendritic cells and other cells
of the innate immunity are activated artiﬁcially via so called
pattern recognition receptors (PRRs) [130, 131]. This highly
conserved family of receptors is widely expressed among
diﬀerent cells in all vertebrates and is an essential part of
the innate immunity [128]. PRRs recognize molecular pat-
terns, which are highly conserved motifs in the structure of
organisms such as bacteria, virus, and protozoa. Activation
of PRRs generally signals danger and leads to a complex
immune reaction [128, 131].
Members of the toll-like receptor (TLR) family are con-
sidered the most intensely studied PRRs. So far, 13 receptors
localizedondiﬀerentimmunecellshavebeendescribed,each
uniqueinitsabilitytorecognizemolecularpatternsfromfor-
eign organism as part of the natural immune defense mech-
anism. For example, TLR4 binds lipopolysaccharide from
Gram-negative bacteria, TLR7 and TLR8 bind speciﬁc mo-
tives in RNA of certain virus, and TLR9 binds CpG motifs of
bacterial DNA. Immune response generally involves but is by
no means limited to an INFγ response [128].
In recent years, it has become evident that ligands against
PRRs can be used in order to stimulate the immune system
and thereby enhance the natural ability of the human body
to ﬁght malignancy and virus infection [130, 131]. This has
created hope that such molecules could have great antitumor
potential and can be used as part of modern adjuvant anti-
cancer strategies. In our previous publications, we described
the activation of the innate immune system with small,
single-stranded RNA molecules leading to IFN-γ production
by NK cells and CD8-T-cells and enhanced antitumor
activity of these cells against target cells [132–134].
Therefore,whilechronicinﬂammationisproventocause
cancer on the one hand, it seems that speciﬁc, partial ac-
tivation for a deﬁned period of time potentially might have
the exact opposite eﬀect, and the latter could be used as part
of anticancer strategies via ligands of speciﬁc PRRs.
Another important, related aspect is the ability of SP to
modulate the immune response. In cancer patients, both
adaptive and innate cell-mediated immunity failed to pre-
vent the development of the primary tumor but may be
extremely important in eradicating residual diseases and in
controlling metastasis [135, 136]. The high incidence in
tumor recurrence after major surgeries might be, in fact, due
to immunosuppression. Among several aspects of surgery
involved in immunosuppression, the local neurogenic proin-
ﬂammatory response initiated by nociceptive aﬀerent nerve
endings may have a prominent role [137]. It involves local
and spinal reﬂexes and promotes erythema and edema
around the surgical wound by releasing numerous com-
pounds, including SP [138, 139]. Tachykinins, especially SP,
may contribute to the enhancement in systemic levels of
proinﬂammatory cytokines (interleukin (IL-6 and IL-8))
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other factors interfering with the cellular immunity (IL-10,
IL-1rA, soluble tumor necrosis factor-α receptor sTNF-αr,
sIL-2r) observed after surgery [140–142].
5.Emotional Behaviour,NK-1 Receptor,
andCancer
Since the beginning of the 20th century, awareness has been
raised regarding psychosocial factors being implicated in
the incidence and progression of cancer. The eﬀect of these
factors on tissues is thought to be a reﬂection of the release
of certain, speciﬁc hormonal transmitters from cells of the
neuroendocrine system. We have previously reﬂected this
fascinating aspect of cancer pathology in depth [143]. The
concise overview presented here is intended to outline the
importance of this concept when developing modern, future
anticancer strategies.
Depression and cancer co-occur commonly. The preva-
lence of depression among cancer patients increases with
disease severity and symptoms such as pain and fatigue. New
evidence supports the notion that emotional distress and
nonexpression of emotions may adversely aﬀect the clinical
course of cancer [143]. Past research on the relationship
between depression and cancer risk provided somewhat
inconsistent evidence, and recent studies have suggested that
chronic depression is a greater risk factor than episodic de-
pression. Moreover, there is evidence that providing psy-
chosocial support reduces depression, anxiety, and pain and
may increase the survival time of cancer patients [143]. In
this sense, there is evidence to suggest that factors related to
lifestyle, such as exposure to various forms of stressors, are
associated with mammary tumorgenesis. The possible role
of life-style factors in breast cancer is important because the
mortality due to this disease is increasing in most countries
and the development of curative therapies for breast cancer
has not been forthcoming for years. The crucial factor
aﬀecting tumor growth is the interaction between stressors,
an individual’s personality, and the available psychosocial
support, as well as the eﬀect of their interaction on an
individual’s ability to cope with stress [137, 144, 145].
It must also be emphasized that there are other possible
mediatingmechanismsfortheinﬂuenceofpsychologicalfac-
tors besides the classical psychoneuroimmunological (PNI)
pathway, such as the above-mentioned neoangiogenesis as
part of a favourable tumor microenvironment [146]. Several
cytokines, including interferons, angiogenin, tumor necrosis
factor, transforming growth factors and interleukin-8 (IL-8),
regulate this process. Since some studies have demonstrated
an eﬀect of psychological factors on cytokine production, a
more speciﬁc, albeit speculative, PNI hypothesis can be pro-
posed for the inﬂuence of immunological factors on tumor
growth [147]. It has been reported that psychotropic drugs
modify the expression of the genes encoding the synthesis
of tachykinins and the expression of the NK-1 receptor in
selected brain areas [148–150]. It is known that chronic
treatment with antidepressant drugs produces a decrease
in the concentrations of SP in several areas of the central
nervous system, including the striatum, substantia nigra,
and the amygdala. These ﬁndings suggest that a reduction
in SP levels in certain brain regions could contribute to a
common therapeutic eﬀect of antidepressant drugs in aﬀec-
tive disorders [137, 151].
SP and NK-1 receptors are present in the limbic system,
including the hypothalamus and the amygdala. In addition,
SP may be involved in the integration of emotional responses
to stress, suggesting the possibility that the pathogenesis of
depression could be due to an alteration of the SP/NK-1
receptor system [34]. In fact, in depression, an increase in
the production of SP has been observed. In addition to
the involvement of SP in depression, the NK-1 receptor
antagonist L-733,060 has been used as an antidepressive
agent [34, 35], and it has been demonstrated that this
antagonist has antitumor activity against human glioma,
neuroblastoma, melanomas, retinoblastoma, and pancreatic
carcinoma cell lines [18, 20, 21, 23–25, 127]. Moreover, it
is known that the NK-1 antagonist aprepitant (MK869), an
agent structurally unrelated to L-733,060 or L-732,138 with
antidepressant activity, is as eﬃcient as the antidepressant
drug paroxetine in the treatment of depression. Aprepitant
is well tolerated, and no statistically signiﬁcant diﬀerences
in the frequency of adverse events as compared to placebo
administration have been observed [34].
These data suggest that depression could induce tumor
cell proliferation by activating the SP/NK-1 receptor system
and that treatment with NK-1 receptor antagonists could
be useful not only in depression, but also for the treatment
of tumor cells. Moreover, all the above data indicate that
emotional behaviour, for example, depression, and cancer
are related through alterations in the SP/NK-1 receptor
system[43,145,152,153].Accordingly,throughthisreceptor
system, there could be an interrelationship between the
progression of cancer and cerebral mechanisms. The NK-1
receptor expressed in the limbic system is similar to the
NK-1 receptor expressed in human tumor cell lines, and SP,
after binding to NK-1 receptors located in the limbic system,
produces anxiety and depression, whereas after binding to
the NK-1 receptor of human tumor cells, SP induces cell
proliferation. Therefore, the NK-1 receptor antagonists in
thelimbicsystemexertantidepressantandanxiolyticactions,
while the NK-1 receptor antagonists in human tumor cell
lines have antitumor action.
On the other hand, the cytokine response, not only
to surgery but also to stress, is intertwined with the neu-
roendocrine response. During the perioperative period and
following psychological stress and anxiety, neuropeptides
including tachykinins [154] are released systemically as well
as locally by nerve endings that are believed to form
“synapses” with leukocytes [141, 148, 155]. Moreover, it has
been reported that regional anesthesia and analgesia may
helptoattenuatethesurgicalstressresponsebyinhibitingthe
release of SP from nerve ﬁbers. In this sense, SP could be one
oftheperioperativefactors,assuggestedbyothers[152,156],
whichincreasetumorgrowthandspreading.Thesequestions
require future investigation for conﬁrmation, but it leads us
to believe that it is quite possible that, as in pain and in neu-
rogenic inﬂammation, in tumor progression, in angiogene-
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receptors by SP plays an important role. Hence, the SP/NK-
1 receptor system, after being blocked with NK-1 receptor
antagonists or regional anesthesia, could be involved in the
recurrence of cancers overexpressing NK-1 receptors [157].
6. NK-1 Receptor Antagonists
Substantial eﬀorts have been made to develop therapeu-
tic inhibitors against NK-1 receptors in the last decade.
Small molecules as antagonists of the NK-1 receptor have
represented an important opportunity to further exploit
compoundsthatareactiveagainstthisreceptorasnovelther-
apeutic agents [158]. The current NK-1 receptor antagonists
have been recently examined in detail by Mu˜ noz et al. [66].
In general, distinction is made between peptide antag-
onists and nonpeptide antagonists. With regards to peptide
antagonists, most work carried out on the design and
preparation of antagonists of the NK-1 receptor has focused
on the introduction of D-amino acids [159]. However, their
aﬃnity is several orders of magnitude lower than that of
naturalagonists,andthemetabolicinstabilityofpeptideNK-
1 receptor antagonists and their inability to gain access to
the central nervous system through the blood-brain barrier
limits their usefulness for in vivo studies. In addition, after
administration in the central nervous system, these sub-
stances generally suﬀer from a number of drawbacks, such as
poor potency and an inability to discriminate between
tachykininreceptors,partialresidualagonistactivity,degran-
ulation of mast cells, and neurotoxicity [160, 161].
The pitfalls encountered with the development and use
of peptide antagonists against the NK-1 receptor lead to
the search for alternative receptor antagonists. Diﬀerent
research groups searched for NK-1 receptor antagonists by
screening a wide variety of chemical collections. Eastman
KodakandSterlingWinthropinitiallyproposedsteroidcom-
pounds as tachykinin NK-1 receptor antagonists, but they
had insuﬃcient aﬃnity for the NK-1 receptor [160, 162].
Moreover, these compounds proved to have signiﬁcant
toxicity. Although many derivatives of steroid compounds
have been synthesized, their biological activity has not
improved. Rhone-Poulnec proposed the compound RP-
67,580, which showed a high aﬃnity for the NK-1 receptor
in rats and mice, but not in humans [160, 162]. Pﬁzer
proposed a benzylamino quinuclidine structure called CP-
96,345 [163]. It was a rather simple structure composed of a
rigid quinuclidine scaﬀold containing a basic nitrogen atom,
a benzhydryl moiety, and an o-methoxybenzylamine group.
This compound showed high aﬃnity for the NK-1 receptor
but also interacted with Ca2+-binding sites, which caused a
number of systemic eﬀects unrelated to the blocking of the
NK-1 receptor. The compound CP-99,994 was synthesized
by replacing the quinuclidine ring by a piperidine ring
and the benzhydryl moiety by a benzyl group. CP-99,994
showed a high aﬃnity for the human NK-1 receptor, and
several structure-activity studies were carried out in order
to identify the structural requirements vital to increase its
aﬃnity for the NK-1 receptor. These studies reached a phase
II clinical trial, but no further studies were carried out owing
to its poor bioavailability. Pﬁzer obtained other related NK-
1 receptor antagonists, for example, CJ-11,974, also called
ezlopitant;itisacloseanalogueofCP-96,345andcontainsan
isopropylgrouponthemethoxybenzylring.Itwasdeveloped
up to phase II clinical trials for chemotherapy-induced
emesis. CP-122,721 is a CP-99,994 analogue that contains
a triﬂuoromethoxy group in the o-methoxybenzyl ring. It
reached a phase II trial for the treatment of depression,
emesis, and inﬂammatory diseases but ultimately failed. In
1993, Merck initiated studies on NK-1 receptor antagonists,
based on both CP-96,345 and CP-99,994. L-733,060 is one
of the compounds developed from CP-99,994 (Figure 4).
It is a 3, 5-bistriﬂuoromethyl benzylether piperidine [164].
It is known that the administration of L-733,060 produces
analgesia [33] and antidepressive eﬀects [34, 35]. The com-
pound has been suggested for the treatment of anxiety and
mood disorders [165] and in inﬂammatory liver disease,
most likely owing to its ability to inhibit the eﬀects of SP
[166]. In addition, it has been reported by our group that L-
733,060 acts as an antitumor agent in several human tumor
cell lines [18, 20, 21, 23–25, 127] (see Figure 3).
Further changes in the chemical structure of NK-1 re-
ceptor antagonists have created certain advantages. A mor-
pholine nucleus that was introduced in L-742,694 was
found to enhance NK-1 receptor-binding aﬃnity [167]. This
nucleus was kept in further modiﬁcations. In order to pre-
vent possible metabolic deactivation, several reﬁnements,
such as methylation on the C alpha of the benzyl ring and
ﬂuorination on the phenyl ring, were carried out. These
changes aﬀorded the compound MK-869, which showed
high aﬃnity for the NK-1 receptor. MK-869 is also called
aprepitant (Figure 4) and is used for the treatment of pain,
migraine,emesis,andpsychiatricdisorders.Thesestudiesled
the Food and Drug Administration (FDA) to approve the
drug Emend, which is indicated for chemotherapy-induced
nausea and vomiting and is available for oral use [168]. A
water-solublephosphorylprodrugforintravenoususe,called
fosaprepitant, is also available and is marketed as Ivemend
[169]. It seems that aprepitant is eﬀective for the treatment
of depression [34, 35] and cancer [170, 171].
7.Effects ofNK-1 Receptors Antagonists
7.1. Antitumor Eﬀects of the NK-1 Receptor Antagonists. In
recent years, it has been demonstrated that L-733,060 dis-
plays antitumor activity against a large variety of cancer cell
lines, including human SKN-BE(2) neuroblastoma, GAMG
glioma, COLO 679, COLO 858, and MEL HO melanoma,
WERI-Rb-1 and Y-79 retinoblastoma, and CAPAN-1 and
PA-TU 8902 pancreatic, HEp-2 larynx, 23132/87 gastric, and
SW-403 colon carcinoma cell lines and T-ALL BE-13 and B-
ALL SD-1 leukemia cell lines [18, 20, 21, 23–25, 127] (see
Figure 3).
Another NK-1 receptor antagonist, L-732,138, also elicits
antitumor action against several human tumor cell lines
(see Figure 3). Analysing the mechanisms for the observed
antitumoral eﬀect, it was demonstrated that the antitumor
action is due to speciﬁc binding of the NK-1 receptor10 The Scientiﬁc World Journal
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Figure 3: Cytotoxicity in human cell lines induced by NK-1 receptor antagonists. An up-to-date outline of our so far published results is
shown for the antitumor eﬀect of NK-1 receptor antagonists (a) L-732,138, (b) L-733,060, and (c) aprepitant in a variety of human cell
lines of diﬀerent tissues including glioma, neuroblastoma, retinoblastoma, melanoma, carcinoma of pancreas, larynx, stomach, and colon.
Concentrations of the antagonists are shown in μMolar for each cell line corresponding to 50 and 100 percent inhibition by cytotoxicity
assay.
(a) (b)
(c)
Figure 4: The chemical structure is shown for L-732,138 (a), L-733,060 (b), and aprepitant (c). Hydrogen elements are symbolized in white,
carbon in grey, nitrogen in blue, oxygen in red, and ﬂuorine in yellow colors.The Scientiﬁc World Journal 11
antagonists to the human NK-1 receptor. Thus, exogenous
SP-induced cell proliferation was partially reversed by the
administrationofL-733,060orL-732,138.Thisindicatesthat
the antitumor action is speciﬁc and related to the ability of
these antagonists to block the NK-1 receptors expressed by
these tumor cell lines. It has also been demonstrated, as
previously indicated, that the NK-1 receptor antagonist L-
733,060 inhibits the metastatic progression of NK-1 re-
ceptor-expressing cancer cells [18, 19, 21–23, 25, 53, 172].
Furthermore, this antagonist binds speciﬁcally to the human
NK-1 receptor-expressing cells in human breast carcinoma
[153]. The growth inhibition observed in the above-reported
human cancer cell types using the NK-1 receptor antagonists
L-733,060 or L-732,138 is in agreement with the ﬁndings of
other studies, in which the use of SP antagonists other than
L-733,060/L-732,138 inhibited the growth of small cell lung
cancer and the U373 MG glioma cell line [173, 174]. More-
over, these data are also in agreement with a recent study,
in which the NK-1 receptor antagonist aprepitant was used.
This drug is a broad spectrum antitumor drug which acts
in vitro against neuroblastoma, glioma, retinoblastoma, and
pancreatic, larynx, gastric, colon carcinoma, and leukaemia
cell lines [18, 171] (see Figure 3).
As illustrated in Figure 3, L-733,060, L-732,138, and
aprepitant induced growth inhibition by apoptosis in human
A-204rhabdomyosarcoma,inSKN-BE(2),KELLY,andIMR-
32 neuroblastoma, in WERI-Rb-1 and Y-79 retinoblastoma,
and in HEp-2 larynx, 23132/87 gastric, SW-403 colon car-
cinoma, and T-ALL BE-13 and B-ALL SD-1 cell lines [18,
22, 23, 25, 53, 54, 149, 175]. This is in agreement with other
reports, since it is known that SP antagonists other than that
mentioned above induce apoptosis in lung cancer and cause
a concentration-dependent loss of cell viability [176].
It seems that the antitumor activity of the NK-1 receptor
antagonists is a speciﬁc action and not a general toxic eﬀect
[5].Wheninterpretingtheseﬁndings,onemustbearinmind
several important concepts. First, all the mentioned cell lines
in which a robust antiproliferative eﬀect can be induced by
NK-1 receptor antagonists highly express NK-1 receptors.
Further, the antitumor action of NK-1 receptor antagonists
is dose dependent.
The NK-1 receptor antagonists L-733,060, L-732,138,
and aprepitant are designed molecules that bind speciﬁcally
to this receptor, with a Ki value of 0.8mM in the case
of L-733,060, of 2.3nM for L-732,138, and of 0.2nM for
aprepitant. Thus, molecules that have structural similar-
ities with NK-1 antagonists such as piperidine (similar
to L-733,060), L-tryptophan (similar to L-732,138), and
morpholine (similar to aprepitant, see Figure 4) exert the
same antitumor action only by having in common their
speciﬁcity for the NK-1 receptor. The blockade of NK-1
receptors in the above-mentioned human cell lines by L-
733,060, L-732,138, or aprepitant was shown to inhibit both
DNA synthesis and cell proliferation through the MAPK
pathway [15] and additionally was found to inhibit the
formation of a β-arrestin-containing complex that allows
nuclear translocation of ERK1/2 and a decrease in the
basal activity and expression of Her2 and EGFR inhibiting
proliferation and inducing apoptosis [16, 177].
The foregoing data suggest that the antiproliferative
action of the NK-1 receptor antagonists L-733,060, L-
732,138, and aprepitant, once bound to the NK-1 receptors
located in the tumor cells, most likely involves the inter-
action with a signal transduction pathway for apoptosis. It
should be noted that in cell lines as diﬀerent as human
neuroblastoma, glioma, retinoblastoma, larynx carcinoma,
and leukaemia the same NK-1 receptor antagonist (L-
733,060,L-732,138, or aprepitant) elicits growth inhibition.
This suggests the possibility of a common mechanism for
cancer cell proliferation mediated by the SP/NK-1 receptor
system. If this would result correctly, it would mean that
NK-1 receptor antagonists could inhibit a large number of
tumor cell types in which both SP and NK-1 receptors
are expressed, and that they could be candidates for broad
spectrum antineoplastic drugs [18, 22, 23, 25, 41, 53–55,
178–181].
It is also well known that SP activates malignant glial
cells by inducing cytokine release and proliferation, both
responses being relevant for tumor progression. The role of
SP in supporting glioma progression in vivo is highlighted by
the tumor growth inhibition induced by highly speciﬁc and
selectivehumantachykininNK-1receptorantagonists(MEN
11,467 and MEN 11,149). The antitumor activity of MEN
11,467 was observed in both subcutaneous and intravenous
treatments, and it was partially reversed by the concomitant
administration of exogenous SP. These ﬁndings suggest a
novel approach for the treatment of malignant gliomas with
tachykinin NK-1 receptor antagonists [173]. Furthermore,
the antitumor activity of NK-1 and NK-2 receptor antag-
onists has been demonstrated in nude mice, measuring
growth inhibition of MDA-MB-231 tumor cells xenografted
subcutaneously. A signiﬁcant inhibition was found when the
compounds were administered intravenously (5mg/kg per
dayfor2weeks).Theseresultssuggestthattheinvivoactivity
of NK-1 and NK-2 antagonists may be a result of a cytostatic
eﬀect rather than a cytotoxic eﬀect [173, 182]. Moreover, it
has been reported that SP antagonists exert an antitumor
actioninaxenograftmodelofahumanprimarycolontumor
cell line [183]. These ﬁndings are consistent with previous
evidences showing that the inhibition of TAC1 expression by
small interfering RNA in breast cancer cells shows a lack of
tumorigenic phenotype and an inhibition of bone marrow
metastasis in nude mice [39], while overexpression of NK-1
receptor leads to a transforming phenotype [184].
7.2. Inhibition of Angiogenesis and Migration of Tumor Cells.
Neoangiogenesis, a hallmark of tumor development, has
been associated with increased tissue innervation and the
expression of NK-1 receptors [41]. As mentioned above, it
is known that in a large majority of tumors investigated, SP
and NK-1 receptors were found in the intra- and peritumor
blood vessels [58]. A well-studied example of this high ex-
pression of NK-1 receptors in blood vessels not only within
the tumor mass but also in the peritumorous tissue is pan-
creatic cancer [55]. It is known that SP analogue antagonists
(SPA), synonymous of NK-1 receptor antagonists, block the
endothelial proliferative action of SP, and that SPAs exert12 The Scientiﬁc World Journal
antitumorigenic activities. SPA, in vitro, inhibits multiple
neuropeptide-induced Ca2+ mobilization, DNA synthesis,
and growth in ductal pancreatic cancers. SPA also signiﬁ-
cantly attenuates the growth of HPAF (human ductal pan-
creatic adenocarcinoma)-II tumor xenografts in nude mice;
markedly increases apoptosis, but only moderately decreases
proliferation markers; markedly reduces tumor-associated
angiogenesis in the HPAF-II xenografts in vivo; attenuates
tumor growth in pancreatic cancer via a dual mechanism
involving both antiproliferative and antiangiogenic actions
[185]. These actions are likely to be related to the presence
of NK-1 receptors in the tumor and in the endothelial cells
[55, 58, 186]. Thus, the NK-1 receptor target could be used
for the inhibition of angiogenesis, since it is known that
SP stimulates vessel growth by enhancing endothelial cell
proliferation and that, in vivo, angiogenesis is mimicked
by selective NK-1 receptor agonists and inhibited by NK-1
receptor antagonists [46].
As mentioned above, development of metastasis can be
explained in terms of the notion that GPCRs regulate the
migratory activity of tumor cells. This means that ligands of
thesereceptorscouldinducethemigrationoftumorcellsand
that migration could be regulated by signaling substances,
including neurotransmitters. These could induce a metas-
tatogenic tumor cell type by regulating gene expression and
by increasing migratory activity. Accordingly, this activity
can be prevented by neurotransmitter antagonists. It has
also been reported that NK-1 receptors are present in the
MDA-MB-468 breast cell line and that L-733,060 completely
inhibitedtheSP-mediatedincreasingmigratoryactivity[78].
Moreover, it has been described that in patients with breast
cancer the risk of recurrence or metastasis is reduced four-
fold during a 2.5-to-4-year follow-up period when surgery
was associated with paravertebral anesthesia [142, 149, 156].
It seems that this occurs because paravertebral anesthesia
blocked SP-induced migration, invasion, and metastasis of
the tumor cells. Taken together, tumor-cell migration is a
prerequisite for invasion, and metastasis and is dependent
on the signaling substances of the immune, nervous, and
neuroendocrine systems. Thus, the SP/NK-1 receptor system
could regulate the growth of the tumor mass, the peritumor
inﬁltration, and the metastasis, since in tumor cells and in
t u m o ra n dp e r i t u m o rt i s s u e s ,t h i sr e c e p t o rs y s t e mi sh i g h l y
overexpressed [55, 58].
7.3. Additional Eﬀects. A variety of additional eﬀects have
been observed for NK-1 receptor antagonists. Recently, an in
vitro study has demonstrated that L-733,060, combined with
vinblastine or microtubule perturbing agents, is synergistic
for the growth inhibition of the NK-1 receptor-possessing
cancer cell lines (T98G, U87, Hela, T24, and MDA-MB-
231), but not for normal lung IMR-90 ﬁbroblast cells.
This indicates that this combination is more potent against
the NK-1 receptor overexpressing cancer cells and that
the interaction between these molecules, the microtubule
destabilizing agents (MDAs) and the NK-1 receptor antag-
onists, might be clinically useful (e.g., aprepitant has been
approved by the FDA as an antiemetic for chemotherapy-
induced emesis). These data demonstrate the usefulness of
the MDAs and the NK-1 receptor antagonists to predict
novel relationships between diﬀerent classes of compounds
for cancer chemotherapy [187].
Furthermore, it has been reported that the antineoplastic
agent cyclophosphamide and the radiation can, respectively,
produce neurogenic inﬂammation in the urinary bladder
and in the gastrointestinal tract, such inﬂammation being
mediated by NK-1 receptors. In this sense, the administra-
tion of NK-1 receptor antagonists in combination with cer-
tain cytostatic drugs and radiation therapy has a dual eﬀect;
it exerts a synergistic antitumor action, and it decreases
cytostatic and radiation therapy side eﬀects [188, 189]. It is
also known that NK-1 receptor antagonists reduce plasma
protein extravasations caused by antineoplastic drugs. In this
sense, it seems that the neurogenic inﬂammation induced
by cytostatics and radiation therapy is mediated by the
release of SP from nerve terminals. Thus, after binding to
NK-1 receptors located in the blood vessels, SP increases the
permeability of these vessels, resulting in an extravasation
of plasma proteins. This means that by blocking the NK-1
receptors with NK-1 receptor antagonists, the triggering of
the inﬂammatory cascade could be aborted, and hence the
lysis or apoptosis of neutrophils, enhanced by inﬂammatory
mediators, is considerably decreased. These ﬁndings are very
important, because cytostatics and radiation produce, ﬁrst,
an inﬂammation of the mucosa and, second, a breakdown of
the mucosal barrier. These sites are a gateway for germs and
elicitsystemicinfection,whichisexacerbatedbyneutropenia
secondary to the use of radiation and cytostatics. In contrast,
the use of NK-1 receptor antagonists improves neurogenic
inﬂammation, whether it is caused directly by radiation or
indirectly by inﬂammatory mediators [188, 189].
NK-1 receptor antagonists have been observed to be
eﬀective analgesics. Intravenous administration of the NK-1
receptor antagonist L-733,060 to gerbils before an intra-
plantar injection of formalin caused a dose-dependent and
complete inhibition of the late, but not the early, nociceptive
response phase (paw licking). In contrast, the nonbrain
penetrant quaternary ketone NK-1 receptor antagonist L-
743,310 did not attenuate the response to formalin, indi-
cating that the antinociceptive eﬀect due to the blockade of
NK-1 receptors by L-733,060 is centrally mediated. These
data suggest that NK-1 receptor antagonists can be used as
centrally acting analgesics [28, 33].
One additional eﬀect of NK-1 receptor antagonists
is of particular interest in this context. Due to their
interaction with NK-1 receptors expressed in the cen-
tral nervous system, the antagonists seem to elicit both
anxiolytic and antidepressive eﬀects. Oral administration
of the NK-1 receptor antagonist L-733,060 (10mg/kg,
approximately 30μM) or other NK-1 receptor antagonists
produced anxiolytic-like eﬀects in the gerbil-elevated plus
maze. It is also known that aprepitant (0.01–3mg/kg) is
the most potent NK-1 antagonist producing anxiolytic-like
eﬀects. These data suggest that NK-1 receptor antagonists
may have clinical usefulness in the treatment of a range
of anxiety and mood disorders [165]. In a preclinical
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aprepitant drug (3mg/kg), L-733060 (10mg/kg, 30μM),
or other NK-1 receptor antagonists revealed the anti-
depressant potential of these substances [35]. In a placebo-
controlled trial in patients with moderate-to-severe major
depression, robust antidepressant eﬀects of the drug aprepi-
tant were consistently observed [34] .T h e r ei sc u rr e n t l ya c c u -
mulatingabundantliteratureandscientiﬁcevidenceshowing
that the NK-1 receptor antagonists vofopitant, ezlopitant,
CP-122,721, and the drug aprepitant control chemotherapy-
induced nausea, postoperative nausea, and vomiting [168,
190, 191]. These considerations are of particular interest
when treating not just cancer as an isolated entity of disease,
but when treating a whole person who suﬀers from cancer.
Additional eﬀects of NK-1 antagonists include a potent
anti-inﬂammatory and hepatoprotective eﬀect.Pretreatment
of mice with the NK-1 receptor antagonists CP-96,345 or
L-733,060 (20mg/kg, approximately 60μM) protected mice
from GalN/LPS-induced liver injury. Also, NK-1 receptor
blockade reduced inﬂammatory liver damage (e.g., edema
formationandneutrophilinﬁltration).Theseﬁndingscanbe
interpreted in a way that NK-1 receptor antagonists exert a
hepatoprotective eﬀect [166].
7.4. NK-1 Receptor Antagonists as a Clinical Drug. It is im-
portant to note that the action of NK-1 receptor antagonists
isdosedependent.Furthermore,dependingonthedose,NK-
1r e c e p t o r so fd i ﬀerent localization can be targeted, bear-
ing even greater pharmaceutical potential. The following
concepts are currently accepted with regards to the dosage
of NK-1 receptor antagonists [192]. At low doses, they act
on the NK-1 receptors of the brain stem located in the glos-
sopharyngealnucleus,withanantiemeticactioninsituations
ofintractablevomitingduetocytostatics.Ifthedoseisraised,
the drug acts on NK-1 receptors at the central level in the
limbic system (amygdala, hypothalamus, and areas related
to emotional behaviour), producing an antidepressive and
anxiolytic action. At higher doses, they act on the thalamus
and other brain areas as a central analgesic. Still higher doses
produce an anti-inﬂammatory action, and similar or slightly
higher doses, depending on the tumor in question and its
stage, elicit antitumoral activity by the inhibition of cellular
proliferation, metastases, peritumor inﬂammatory reaction,
and angiogenesis. When used at its highest doses, NK-1
receptor antagonists produce all the pharmacological eﬀects
described above [192].
As mentioned above, NK-1 receptor antagonists specif-
ically bind the NK-1 receptor. Therefore, they act selec-
tively against tumor cells, because these cells express more
NK-1 receptors than nontumoral cells. Also, their action is
longlasting, because they are not hydrolysed by peptidases.
Of particular interest is that these drugs generally can be
administered orally with suﬃcient therapeutic eﬀect, and
that they cross the blood-brain barrier [66].
Moreover, safety and tolerability of the NK-1 recep-
tor antagonist aprepitant was demonstrated in a placebo-
controlled trial in patients with moderate-to severe major
depression. At a dose of 300mg/day, aprepitant was well
tolerated, and no statistically signiﬁcant diﬀerence in the
frequencyofadverseeventswasobservedascomparedtopla-
cebo [34]. Moreover, the safety of aprepitant against human
ﬁbroblast cells has been reported, showing the IC50 for
ﬁbroblast cells to be approximately three times higher than
the IC50 for tumor cells [171].
In resumen, it seems that in addition to being potent
anticancerdrugs,NK-1antagonistsinheritanddeployawide
variety of favourable eﬀects and should without doubt be
considered as new, promising antineoplastic agents amongst
modern anticancer strategies. The 21st century is evolving as
the era of molecular targeted anticancer therapy, leading to
the development of so-called “magic bullets” for anticancer
therapy [171]. Rather than being “magical,” NK-1 receptor
antagonists are proven to combine anticancer eﬀects with
other favourable properties. If these properties hold stand
during sophisticated clinical trails, perhaps they should be
considered not so much “magic” bullets, but “intelligent”
bullets. In this latter, new concept of drug therapy, in one
drug, a potent anticancer eﬀect could be combined with
anti-inﬂammatory, analgesic, anxiolytic, antidepressant, and
antiemetic eﬀects.
8.FutureResearch
The design of new therapies targeting the tumor microenvi-
ronment has been a focus of intense research over the recent
years. The cellular component of the tumor microenviron-
ment includes, among others, tumor-associated ﬁbroblasts,
endothelial and neuronal cells, and cells from the immune
system.
Given the relevance of SP/NK-1 signaling in cancer, sub-
stantial eﬀorts have been made to develop therapeutic
inhibitors against NK-1 receptor. Recently, instead of its
receptor, additional eﬀorts have been made to target the
NK-1 receptor ligand SP. Given the lack of chemical com-
pounds capable of inhibiting this small peptide, the use
of speciﬁc antibodies was used to address the therapeutic
potential of SP inhibition in cancer. In one recent study,
it was found that the use of antibodies against SP induces
cell death in several cancer cell types and that this eﬀect is
accompanied by a decrease in signaling through the MAPK
pathway and a decrease in the basal activity and expression
of Her2 and EGFR [42]. These ﬁndings support the utility of
inhibition of the SP/NK-1 signaling pathway in anticancer
therapy and further suggest that indirectly targeting the
NK-1 receptor via SP might be an alternative pathway for
anticancer treatment. Whether targeting NK-1 via SP can
overcome the caveats that limit long-term eﬀects of NK-1
antagonists is impossible to tell, and further research must
be employed. However, one must bear in mind that, as
described above, the rapid turnover of NK-1 receptors on
the cell surface limits long-term eﬃcacy of NK-1 receptor
antagonists [70]. Thus, blocking SP could potentially target
the signal transduction of other tachykinin receptors given
the ability of this peptide to bind NK-2 and NK-3 albeit with
reduced aﬃnity [29, 193]. Nevertheless, cytokine secretion
mediated by activation of NK-1 receptors is also triggered by
neurokinin A (NKA) [194]; moreover, it has been reported14 The Scientiﬁc World Journal
that substance K, an elongated form of neurokinin A, can
induce mitogenesis [195, 196]. Hence, given the relevance of
the tachykinergic system in cancer progression, the design of
targeted therapies against these molecules continues to be an
attractive approach for the treatment of cancer.
As mentioned above, practically no literature exists re-
garding the expression and function of the SP/NK-1 receptor
system in CSCs. The discovery of CSCs bears enormous
potential for the development of new, promising anticancer
therapeutics, especially for late and recurrent cancer stages.
Given the crucial role of NK-1 and SP in cancer as described
in this paper, it is very likely that this receptor system bears
someroleeitherinthedevelopmentormaintenanceofCSCs.
It is the assignment and challenge to an on-going scientiﬁc
eﬀort to identify this role.
Anotherpromisingapproachinthedevelopmentofalter-
native adjuvant tumor strategies has been the development
of targeted gene therapy. The most encouraging method is
that of small interfering RNA (siRNA), in which essentially
anygenecanbetemporarilysilencedforregulatorypurposes.
This can potentially be used for new anticancer strategies.
One major limitation in the use of siRNA in vertebrates is its
application. siRNA per se has unfavorable pharmacological
properties and needs to be delivered intracellularly in order
to develop a therapeutical eﬀect. It was recently shown
that certain, speciﬁcally designed RNA-molecules can inherit
both of the above-described properties of speciﬁc gene
knockdown of cancer-related targets and the simultaneous
boost of the innate immune system [197, 198]. This makes
these molecules especially attractive for modern anticancer
strategies.Forexample,itisknownthatsimultaneousknock-
downofB-celllymphoma(Bcl)2andRIG-I-dependentIFN-
induction is superior to either therapy alone in an in vivo
melanoma mouse model [198]. When developing similar,
simultaneous anticancer strategies, NK-1 could potentially
be an applicable target.
9. Conclusions
According to the data obtained from animal experiments,
cell cultures, and clinical studies, it seems that NK-1 receptor
antagonists should be eﬀective in the treatment of aﬀective
and anxiety disorders, pain syndromes, intestinal motility
disorders, and cancer. However, it must be noted that in
many cases, the initial encouraging preclinical results were
followed by a lack of eﬀectiveness in human trials [199–203],
and NK-1 receptor antagonists for cancer treatment have
not yet been successfully translated from the bench to the
bedside.
Nevertheless, as it has been extensively described in this
paper, the NK-1 receptor constitutes an important network
for signal transduction in the cancer microenvironment
and NK-1 receptor antagonists exert three harmonizing
mechanisms: ﬁrst, they have an antiproliferative action due
to the inhibition of tumor cell growth and induction of
apoptosis; second, they inhibit angiogenesis in the tumor
mass; third, they block the migration of tumor cells and
thereby inhibit invasion and metastasis.
Further research and clinical trials must be carried out in
o r d e rt of u ll yr ev e a lt h eb e n e ﬁ c i a le ﬀects of NK-1 antagonists
in the treatment of patients suﬀering from cancer. Given the
encouraging evidence reviewed in this paper, this task is both
exciting and auspicious.
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